This article was originally published in The Tan Sheet
Firm receives tentative approval March 10 for ranitidine 75 mg tablets, equivalent to Glaxo Wellcome's Zantac 75. Glaxo received an additional six months of exclusivity for Zantac 75 until June 19 ("The Tan Sheet" Feb. 1, In Brief). More than a half-dozen firms now have tentative ANDA approvals for OTC ranitidine
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC